Peter Van Oyen

<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer et al. · Clinical Cancer Research · 2018 · 171 citations · Full text

Medicine, Oncology, Pharmacology +17

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington et al. · Genome Medicine · 2018 · 132 citations · Full text

Medicine, Molecular Genetics, Oncology +17

The Use of Bladder Mucosa and Combined Bladder Mucosa/Preputial Skin Grafts for Urethral Reconstruction

P.G. Ransley, P.G. Duffy, I. Oesch et al. · The Journal of Urology · 1987 · 90 citations

Medicine, Surgery, Urology +17

URINARY INCONTINENCE IN BELGIUM; PREVALENCE, CORRELATES AND PSYCHOSOCIAL CONSEQUENCES

Herman Van Oyen, Peter Van Oyen · Acta Clinica Belgica · 2002 · 64 citations

Medicine, Urology, Female Urology +8

Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with castration‐resistant prostate cancer

Bram De Laere, Steffi Oeyen, Peter Van Oyen et al. · The Prostate · 2018 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17